Eyepoint Pharmaceuticals appoints Campbell to boost product launches

robot
Abstract generation in progress

Eyepoint Pharmaceuticals has appointed Michael Campbell as Chief Commercial Officer (CCO) to enhance its product offerings and market presence. Campbell brings over 30 years of commercial leadership experience and a strong background in successful product launches. His role will be crucial in the company’s aim to deliver the first sustained-release TKI to patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)